RRR Pitch Deck

PROUDLY PRESENTED BYThe CellAEDTM is in development. Copyright CellAED Life Saver Pty. Ltd.

CONFIDENTIAL

CONFIDENTIAL

PROUDLY PRESENTED BY

This Pitch Deck has been prepared on the basis of information

provided by Rapid Response Revival Research Limited ACN 617

494 890 (Rapid Response Revival, RRR or the Company). Rapid

Response Revival has authorised the distribution of this Deck to

a limited number of persons to provide information concerning

the Company which may assist the Recipient in deciding whether

to invest in the Company.

This Deck is supplied subject to the conditions outlined on pages

25 & 26 (Conditions of Deck).

Retaining this Deck and/or referring to this Deck evidences the

Recipient’s acceptance of these Conditions. If the Conditions are not

acceptable to the Recipient, this Deck along with any other information

provided to the Recipient must be returned to the Company

immediately.

CONFIDENTIAL

The CellAEDTM is in development. Copyright CellAED Life Saver Pty. Ltd.

The CellAED® is in development. Copyright of Rapid Response Revival Research Limited.

• Sudden Cardiac Arrest is a leading cause of death, attributed to 20% of all deaths

annually, the majority occurring outside of hospitals.

• The success of the Public Access Defibrillator (PAD) system is greatly hampered due to

outdated design & technology.

• CellAEDTM is a world first ubiquitous personal, easy to use, affordable, and connected

medical device to address the low survival rates of sudden cardiac arrest.

• Clinical Trials have begun in four Australian & New Zealand Hospitals.

• Demand established with Governments, Enterprises and Registered Training

Organisations.

• Dual manufacturing capabilities have been established in Australia and Taiwan.

• Founded in 2016, Incorporated 2017

• 65 employees

• Australian Developed, Owned, and Manufactured

• Ready–for–Market Medical Device

• CE Mark awarded

• ISO 13485

• Radio Equipment Directive certified

• Regulatory certification pathways underway in multiple jurisdictions

• Clinical Equivalence supported by independent Clinicians

• Orders for 20,000 units New Zealand

• EOI 3,600,000 units from International Distribution Partners

• Multiple Granted and Pending Patents, Trademarks & Designs.

• Industry leading, proprietary Rhythm Recognition Detector (Classifier) for sensitivity & specificity.

4

CONFIDENTIAL


“My partner had a sudden

cardiac arrest at home in

2014 and miraculously

survived against the odds.

This product will now protect

my family and yours.”

Donovan Casey, Co-Founder, CEO & Executive Chair

The CellAEDTM is in development. Copyright CellAED Life Saver Pty. Ltd.5

CONFIDENTIAL


2 mins 3 mins 4 mins 5 mins 6 mins 7 mins 8 mins 9 mins 10 mins 11 mins

MINUTES TO DEFIBRILLLATIONC

HA

NC

E O

F S

UR

VIV

AL

2


1. Sudden Cardiac Arrest Survivorship: A Scientific Statement From the American Heart Association. Circulation. Feb 2020;141:e654–e685.

2. The Latest Cardiac Arrest Survival Rates in Victoria – 7 Shocking Facts you must know. St John 11 February 2019

3. ‘Public Access Defibrillation. Where Does It Work?’, Circulation. 2009;120:461–463

4. ‘Strategies to Improve Cardiac Arrest Survival: A Time to Act.’, 2015. Committee on the Treatment of Cardiac Arrest: Current Status and Future Directions; Board on Health Sciences Policy; Institute of Medicine

5. CARES Cardiac Arrest Registry to Enhance Survival 2018 Annual Report. Page 22-23

6. ‘Public Defibrillation: Increased Survival From a Structured Response System’, The Journal of Cardiovascular Nursing: November-December 2004 - Volume 19 - Issue 6 - p 384-389

7. Barriers and facilitators to public access defibrillation in out-of-hospital cardiac arrest: a systematic review. European Heart Journal - Quality of Care and Clinical Outcomes (2017) 3, 264–273.

6

•

•

•

•

•

CONFIDENTIAL

PROUDLY PRESENTED BYThe CellAEDTM is in development. Copyright CellAED Life Saver Pty. Ltd.

0.3kg vs 1.9kg

188 x 11.2 x 85 mm

SNAP, PEEL, STICK ®

US$150 * vs US$1500

7

CONFIDENTIAL


•

•

•

•

•

•

•

•

•

•

INNOVATION FEATURES

The CellAEDTM is in development. Copyright CellAED Life Saver Pty. Ltd. 8

CONFIDENTIAL

The CellAED® is in development. Copyright of Rapid Response Revival Research Limited. 9

Established AED manufacturers focus on the hospital supply, missing many of the 70+% of sudden cardiac arrests that occur outside of hospitals.

• We estimate the Public Access AED market is valued at US$ 4.5B annually 1.

• Hospitals & EMS remain a priority for global manufacturers, catering to a high volume / low margin business model.

• Traditional AED manufacturers have attempted but they were not able to accompany the technology with the economics.

• “The public access market is only about 15 percent penetrated. The economics of the market today do not support our industry doing core technology innovation.” Brian Webster, President & CEO Physio-Control to 2006-2016.

• ICD implantation is a larger market of focus for existing manufacturers.

Medium term divergence between manufacturers who focus on the In-Hospital vs Out-of-Hospital segments expected.

• Selling to home and personal channels would require establishing new channels to reach individual consumers.

• RRR anticipates that there will be a divergence in the AED players that primarily focus on the needs of hospital versus out-of-hospital customers.

Sources & Notes: 1. US $4.5B = Physio-Control revenue with market share est. at 20% + 40% distribution margin.

CONFIDENTIAL

PROUDLY PRESENTED BYThe CellAEDTM is in development. Copyright CellAED Life Saver Pty. Ltd. 10

CONFIDENTIAL


Donovan CaseyB.Sc.

Co-Founder, CEO &

Executive Chair

Erol TeberB.E, M.Sc.

Co-Founder,

Director

Simon ShieldsB.Com (Hons), LLB, MBA. CFA

Non-Executive

Director

John HainesA.D.H.Sc (Ambulance), MICA

Non-Executive

Director

Greg BodkinBE (Hons), MComm

Non-Executive

Director

Robert KarpBSc,

Non-Executive

Director

• 25+ years founding

experience across

multiple industries.

• Bachelor of Science,

Pure and Applied

Mathematics,

• Graduate training in

Materials Engineering

and Economics

• Completing an MBA at

MGSM

• Biomedical Electronics

Engineer

• 30+ years global

experience Project

Development &

Technical Sales.

• Worked with Philips

Medical, IBM

Microelectronics &

Royal Prince Alfred

Hospital Cochlear Unit

• Equity Analyst & Fund

Manager

• Founded Monash

Investors 2012.

• Formerly of:

• Westpac/Rothschild

• Colonial First State

(Head of Australian

Equities)

• UBS Global AM (Head

of Australian Equities).

• Former MICA Flight

Paramedic

• Former Deputy Chair,

Australian

Resuscitation Council

(NSW Branch),

• Former President,

Australian Emergency

Care Providers (AECP)

• Founder & Managing

Director of Australia’s

private training

provider, Australian

First Aid in 1988, a part

of the APL Group Pty

Ltd.

• Prolific Author

• Senior Vice President,

Supply Chain &

Operational Excellence

at Cochlear Limited.

• 30+ years experience in

supply chain

management &

operations consulting

positions, new product

industrialisation,

procurement,

manufacturing, logistics

and warranty & repair.

• Experienced technology

executive &

entrepreneur.

• Held CTO & CEO

positions

• 20+ years of experience

in development and

commercialisation of

software solutions.

James OrlandoB.S, MBA

Non-Executive

Director

• NED, Audit

Committee Chair,

Catapult Sport

International Ltd.

• Held CFO positions

with Isentia Group,

Veda Group, AAPT

Limited over his 30+

year career,

11

CONFIDENTIAL


CONFIDENTIAL


For B2B and B2G Sales:

RRR:

▪ Sells via Distributor

Distributor:

▪ Registers devices with RRR

▪ Trains & Assists Customer

▪ Maintains Customer Relationship

Distributor value add:

▪ WHS Training

▪ Public Access Signage

▪ Public Access PlacementDIS

TR

IBU

TO

RS

For B2B & B2C Sales:

RRR:

▪ Sells direct via E-Commerce Platform

▪ Registers Customer device/s

▪ RRR Trains & Assists Customer

▪ RRR Maintains Customer Relationship

Customer Engagement with RRR:

▪ Training

▪ Monthly Text/Email

▪ Evergreen Subscription

DIR

EC

T

13

CONFIDENTIAL


•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

14

CONFIDENTIAL


Jan

21

Feb

21

Mar

21

Arp

21

May

21

Jun

21

Jul

21

Aug

21

Sep

21

Oct

21

Nov

21

Dec

21

Jan

22

Feb

22

Mar

22

Apr

22

CE MDD/MDR Europe MDD ✓ MDR Submission & Review

MedSafe WAND New Zealand ✓

UK Conformity

AssessmentUnited Kingdom Submission & Review

FDA United StatesBreak Through Designation

– 60 Days

Pre Market Approval – 270

Days

CDSCO India Submission & Review – 270 Days

TGA Pre Market

AssessmentAustralia Submission & Review – 255 Days

Taiwan FDA Taiwan Submission & Review – 270 Days

Medical Device

Single Audit

Program (MDSAP)

Australia, Brazil,

Canada, Japan,

USA

Preparation for Submission

No Clinical Trial Data is

Required for Submission

Clinical Trial Data is

Required for Submission

15

CONFIDENTIAL


PATENT & DESIGN

STRATEGYMARKET INTELLIGENCE

• Pursue existing patent family in

key manufacturing and sales

markets.

• Patent claims directed to the

separable board configuration.

• In time, file divisional applications

in select markets to pursue

alternate scopes of protection &

maximise options.

• File new applications to ring-fence

improvements & variations.

• Pursue patent protection for

assembly line processes.

Freedom to Operate (FTO)

Continue with second stage of review.

Competitive intelligence

Regular industry and competitor

specific patent watching searches.

16

Securing Protection Across the Globe

Focus on major customer and manufacturing

jurisdictions.

Country Patent ID

Australia2018211196 *

2017100994 *

United Kingdom1812685.4 *

1909334.3

China 201880001774.2

European Union 18758798.504

United States 16/077,256 *

Russian

FederationRU2020102071 *

Singapore 11201900094X

United Arab

EmiratesP6000181/2019

India 201917007542

Hong Kong 19128202.9

SELECTED PATENTS

TRADE MARK REGISTRATION

CONFIDENTIAL


With CE approval received and clinical trials underway, RRR

expects that at least $13.25m in sales will be achieved, plus pre-

deposits for received for 200,000 CellAEDTM over the next 12

months.

Further Regulatory Approvals

What's required?

FY22F

• No Further Approvals Required

FY23F

• No Further Approvals Required

FY24F

• UK CA + TGA (Aus)

Sales & Distribution

What's required?

FY22F

• Launch of E-Commerce platform.

FY23F

• Larger Sales Team & Marketing Campaigns

FY24F

• Exercise Distributor EOI’s

Production

What's required?

FY22F

• Minor expansion of domestic manufacturing

FY23F

• Commence production from Taiwan manufacturing facility

FY24F

• No additional requirements.

With Capital, minimal operational requirements to achieve financial forecasts

3-Year Financial Forecasts ($USD’)

CONFIDENTIAL

Forecasted Unit Volumes FY22F FY23F FY24F

New Units - New Customers 50,000 250,000 1,250,000

New Units - Renewals at end of life (Ex.Churn) - - 47,500

Existing Units in Circulation - 50,000 250,000

Total Units in Circulation 50,000 300,000 1,547,500

Financial Forecast ($USD’) FY22F FY23F FY24F

Upfront Payments 12,500,000 62,500,000 312,500,000

Monthly Subscription Fee 750,000 29,625,000 157,050,000

Total Revenue 13,250,000 92,125,000 469,550,000

Cost of Sales (12,566,433) (57,323,653) (267,919,456)

Gross Margin 683,567 34,801,347 201,630,544

Gross Margin (%) 5.2% 37.8% 42.9%

Other Income

Government Grants 1,540,000 - -

Operating Expenses

Advertising & Sales Related Costs (951,244) (7,389,009) (31,794,999)

Employment & Professional Fees (10,785,742) (20,728,125) (41,085,625)

General & Administration (5,282,221) (5,988,125) (28,173,000)

Property Expenses (567,816) (1,381,875) (4,695,500)

Research & Development Expenses (4,056,578) (13,818,750) (39,911,750)

Travel & Accommodation (601,855) (2,763,750) (9,391,000)

Total Operating Expenses (22,245,456) (52,069,634) (155,051,874)

EBITDA (20,021,890) (17,268,287) 46,578,670

EBITDA (%) -151.1% -18.7% 9.9%

Cashflow from Operating Activities (23,353,501) (14,153,183) 67,221,297


Underlying Financial Assumptions

1. E-Commerce Platform launched in October 2021 to collect deposits on forward orders.

2. Shipments begin in Q2 FY22.

3. By June 2022, targeting deposits received for 200,000 units.

4. Additional International Manufacturing Facilities commencing production by Q3 2022.

5. Expansion into Australia Q2 FY23 and USA by Q1 FY24.

6. All Revenue and Expenses have been recognised in US$. With main exchange rates

used being:

a) USD/AUD of 0.7700

b) USD/Euro of 0.8200

7. Product Lifecyle of 24 months for the financial forecast period, with no lifetime

improvement (Note: CellAEDTM likely to have extended life beyond 24 months in future

versions of the CellAEDTM)

8. Estimated Renewal Rate of 95% assumed.


Understanding the Revenue Model and Unit Economics:

1. Initial minimum contract of 24 months, where an $250 payment is paid prior

to shipment and 23 monthly payments of $15 thereafter.

2. Revenue Recognised upon receipt of the payment of either the upfront

payment or the monthly subscription fee of $15.

3. At the end of the product life or Contract Term, a new CellAEDTM will be

shipped with no upfront payment required, but instead 24 months of $15

monthly payments.

Revenue Model and Unit Economics

Example of the Unit Economics over the life of the contract:

FY22F FY23F FY24F

New Units - Initial Contract

Revenue over life of the contract $595.00 $595.00 $595.00

CoGS over life of the contract ($251.33) ($229.29) ($206.49)

Gross Margin $343.67 $365.71 $388.51

Gross Margin (%) 57.8% 61.5% 65.3%

New Units - Net Renewals

Revenue over life of the contract - - $360.00

CoGS over life of the contract - - ($206.49)

Gross Margin - - $153.51

Gross Margin (%) - - 42.6%

CONFIDENTIAL


2018 2019 2020 2021 Shareholder TypeCurrent

Position *

CONFIDENTIAL


Regulatory Approvals

Australian Manufacturing

Commercialisation

E-Commerce Platform & B2C Sales

Clinical Trials “Rapid One” Commenced Q2 2021

“Rapid Two”, “Rapid Three” … ongoing

CE Mark, ISO 13485 &

Radio Equipment Directive

Ramp up

from Q2 2021

Deliveries

from Q3 2021

Capacity

Build from

Q4 2021Taiwan Manufacturing

Q4 2021

First Beta Sales New Zealand & Dubai

20

CONFIDENTIAL


CE Mark ✓

ISO 13485 Certified ✓

Radio Equipment Directive Certified ✓

‘Ready to Market’ device ✓

Customer Orders 20,000 units ✓

Production Line Australia ✓

Agreement with Taiwan Contract Manufacturer (OEM) ✓

IP Protection (Multiple granted Patents) ✓

Multi-jurisdiction Design Registrations ✓

Trademark registrations ✓

Multi Disciplined Medical Research Advisory Board ✓

International Distribution Partners ✓

Established demand of 3.6m+ CellAEDTM✓

Clinical partnerships with Medical and EMS stakeholders ✓

21

CONFIDENTIAL


CONFIDENTIAL



Early stage innovation company/pre-revenue.

There is also no certainty that the Company will

successfully execute its business plan and strategies to

ensure that in the future it generates revenues.

Going Concern.

In the opinion of the Company’s Board of Directors there

are reasonable grounds to believe that the Company will

be able to pay its debts as and when they become due

and payable. However, the risks referred to here may

affect that position in future

Competition and new technologies

The Company faces the risk that one or more of its

competitors, or a new entrant into the market may attain

regulatory approval for an AED that rivals the design of

CellAEDTM or is an improvement to its product. If this

materialises, the Company may then compete less

effectively against its competitors and its business,

financial performance and operations could be adversely

affected.

Failure to attain regulatory approvals/failure of

technology

Failures or delays in obtaining regulatory approvals will

impact on the path to market of the CellAEDTM, which

could become extremely costly for the Company as it may

be required to reapply for regulatory approvals.

If any of the key personnel were to depart the organisation it

could negatively impact upon the Company’s ability to

execute its objectives.

Attract and retain key personnel

The Company is reliant on individual staff with specialist skills

and knowledge. There is a risk that the Company may not be

able to attract and retain individual staff members or seek

appropriate replacements for individuals who depart the

organisation. This could cause a material impact upon the

Company’s ability to operate its business and achieve its

objectives.

Current Concentration of shareholders

As at the date of this Pitch Deck, the Company’s founder,

CEO and Chairman Donovan Casey owns either directly or

indirectly through his related entities, approximately 51.48%

of the Company’s fully diluted issued capital. This figure

means that Mr Casey is able to exert significant influence

over matters which require Shareholder approval, including

approval of the Company entering into an IPO event or the

issue of Shares in a financial year which in aggregate amount

to more than 15% of the issued capital of the Company.

Mr Casey is also entitled to, regardless of his effective

shareholding in the Company, to appoint a director under the

Constitution.

Additionally, regulatory regimes change from time to time,

evident with the European Union migrating from a Medical

Device Directive to a Medical Device Regulation. Such regulatory

regimes changes can have an adverse impact on the Company’s

ability to execute its business plan, because it may be required to

test CellAEDTM to different standards using new equipment than

it has previously.

Failure to keep abreast of changes in compliance and

regulatory environments

The Company’s product is significantly influenced and affected

by laws and regulations, which apply to medical devices. As

such, the company has an internal compliance team as part of its

regulatory compliance requirements, which is tasked with

ensuring that CellAEDTM will comply with the regulations within

the jurisdictions it wishes to operate within. The company has

also engaged with external regulatory consultants to add

robustness to its compliance obligations.

While the Company is positioned well to deal with changes in

compliance, there is still the possibility that the Company may fail

to keep abreast of such changes in compliance and the

regulatory environments that it wishes to operate within. Failure

to do so can have a negative financial impact upon the Company

as it will be required at a significant cost to meet new changes to

its compliance obligations.

Reliance on key staff

The Company is reliant on its existing key personnel, who play

an integral role in directing the entity and have an intimate

knowledge of the business, its technology and industry practices.


CONFIDENTIAL


Protection of and exposure to intellectual property

The Company heavily relies on its intellectual property

rights, particularly the patented protection of its product

CellAEDTM within certain jurisdictions in which it is seeking

to sell products. Breach of the Company’s intellectual

property rights may result in the need for the Company to

commence legal action, including infringement

proceedings, which could be costly time consuming and

potentially difficult to enforce in certain jurisdictions.

The grant of IP rights does not inevitably follow after

making an application for such rights. Examination of

patents, for example, may be expensive and time-

consuming, and with no guarantee that patent rights will

be secured.

It is also possible that third parties may assert IP

infringement, unfair competition or like claims against the

Company under patent, trade secret or other laws.

Risks associated with expanding into different

markets

As the Company expands its presence in new

international jurisdictions, it exposes itself to the risks

associated with doing business in those markets that have

political, legal and economic instability or less

sophisticated legal and regulatory systems and

frameworks.

Political, economic or social disruption

Regional political, economic or social disruption (including

lockdowns and restrictions on movement in response to

contagious viruses such as the virus that causes COVID

19) could delay the Company’s progress toward regulatory

approvals and negatively impact manufacturing activity,

with a resulting delay in entry of the Company’s product

into the target markets mentioned in this presentation.

Further, a prolonged period of reduced or negative

economic growth (including a recession or depression) in

any of the Company’s target markets (or in a number of

target markets) could materially and adversely affect

sales, financial performance and profitability.

Speculative Investment

The risks outlines are not an exhaustive list of risks faced

by the Company, and that the risks referred to, and others,

mean that investors should view an investment in the

company as speculative.

Such risks may cause the Company to invest significant

resources and management attention in those

marketplaces.

In order to counteract the possible risks associated with

expanding into different markets, the Company has hired

agents within specific jurisdictions to help it navigate the

legal and regulatory environments of doing business within

that jurisdiction.

Failure to effectively manage growth

The Company has experienced a period of considerable

growth as it ramps up its operations on the assumption

that it will soon gain regulatory approval for CellAEDTM.

The Company expects further growth in the future, which

could place significant strain on current management,

operational and financial resources, as well as the

infrastructure required to manufacture CellAEDTM. The

Company’s future success depends on its ability to

effectively manage this growth particularly as it is still in

the pre commercialisation phase of its operations. Failure

to appropriately manage growth could result in a failure to

commercialise CellAEDTM appropriately and attract

potential customers, which in turn could adversely affect

the Company’s operating and financial performance.


CONFIDENTIAL


1. This Deck is supplied subject to the confidentiality

restrictions contained in a confidentiality agreement

entered into between the Recipient and the Company

(the Confidentiality Agreement). The Recipient should

ensure that they understand these conditions and the

terms of the Confidentiality Agreement. This Deck may

not be photocopied, reproduced, disclosed or distributed

to others at any time without the prior written consent of

the Company. If this Deck was given to the Recipient

without a Confidentiality Agreement, this does not waive

the Recipient’s obligation of confidence and this Deck,

notwithstanding anything else, remains confidential.

2. This Deck does not purport to contain all the

information that may be required to evaluate a possible

investment in the Company. Recipients and their

advisors must conduct their own independent review,

investigations and analysis of Rapid Response Revival

and of the information contained, or referred to, in this

Deck at their own cost.

3. This Deck is intended to provide general information only. It does

not constitute financial product advice, nor does it constitute a

product disclosure statement, prospectus or other disclosure

document required by the Corporations Act 2001 (Cth). This Deck

has not been lodged with the Australian Securities and Investments

Commission (or any other government body). This Deck is

intended only for sophisticated investors, clients of financial

services licensees and professional investors, in accordance with

sections 708(8), 708(10) and 708(11) respectively of the

Corporations Act.

4. The distribution of this Deck in other jurisdictions outside

Australia may also be restricted by law and any such restrictions

should be observed. Any failure to comply with such restrictions

may constitute a violation of applicable securities laws. By

accepting this Deck, you represent and warrant that you are

entitled to receive such presentations in accordance with any such

restrictions and agree to be bound by the limitations contained

herein. Persons who come into possession of this Deck who are

not in Australia should seek advice on and observe any legal

restrictions on distribution in their own jurisdiction. Any failure to

comply with such restrictions may constitute a violation of

applicable securities laws.

5. Some of the information contained in this Deck has

been obtained from third parties. None of that

information, or any other information set out in this

Deck, has been independently verified. None of the

Company, their related entities, directors, officers,

employees or advisors (Information Providers) make

any representation or warranty, express or implied, as

to the accuracy, reliability or completeness of the

information contained in this Deck or subsequently

provided to the Recipient by any of the Information

Providers. This includes, without limitation, any

technical and financial information, estimates and

projections and any other technical and financial

information derived therefrom. Nothing contained in

this Deck is, or shall be relied upon, as a promise or

representation, whether as to the past or the future.

6. To the fullest extent permitted by law, no

Information Provider nor the Company accepts any

liability for any loss or damage suffered or incurred by

the Recipient or any of its related entities or any of

their respective officers, employees, servants, agents,

representatives or advisors or any other person

howsoever caused (including through negligence)

arising in connection with or respect of:

Continued….


CONFIDENTIAL


(a) this Deck including without limitation any

statement, opinion or information contained in it or any

error in or omission from this Deck, or for any lack of

accuracy, completeness, currency, reliability of any

statement, opinion or information in this Deck or

(b) the Recipient, its advisers or any other person

placing any reliance on any statement, opinion or

information set out in this Deck.

7. The information in this Deck does not amount to a

recommendation either expressly or by implication

with respect to an investment in Rapid Response

Revival Research Limited.

8. This Deck contains estimates, forecasts and

forward-looking statements about the Company’s

future business and operations, financial standing and

market conditions. Forward-looking statements are

not guarantees of future performance and are based

on assumptions which are subject to change, many of

which are beyond the control of the Company. Actual

results or performance may differ materially from

those expressed in, or implied by, any forward-looking

statements.

11. The Company reserves the right to evaluate any offers,

to reject any or all offers submitted and to elect not to deal

with Recipient without giving reasons. The Information

Providers will not be liable to compensate the Recipient or

its advisers for any costs or expenses incurred in reviewing,

investigating or analysing any information in relation to the

Company, or in making an offer.

12. The information in this Deck does not have regard to the

investment objectives, financial situation and particular

needs of readers of this Deck

The Recipient must verify to its own satisfaction the

accuracy, reliability and completeness of such information

and obtain independent and specific advice from appropriate

experts.

13. Recipients acknowledge that any investment in the

Company is risky and they may lose their entire investment.

14. Any liability of any Information Provider to a Recipient, its

advisers or to any other person or entity arising out of this

Deck is, to the maximum extent permitted by law, hereby

expressly disclaimed and excluded.

Therefore, the Recipient and their advisers must form their own

views in relation to such matters by undertaking their own due

diligence and independent review of the assumptions and

methodologies upon which the estimates, projections and

forward-looking statements are based.

9. The Information Providers may in their sole and absolute

discretion, but without being under any obligation to do so,

update or supplement this Deck. Any further information will be

provided subject to these conditions and the Confidentiality

Agreement. No Information Provider accepts any responsibility

to inform the Recipient or any of its advisers of any matter

arising or coming to their notice which may affect any matter

referred to in this Deck.

10. This Deck, including any update or supplement to it, does

not and will not form part of any contractual documentation for

an investment in Rapid Response Revival that may result from

the review, investigation and/or analysis of the Company by the

Recipient, any intending acquirers and their respective advisers.

Any formal contract for an investment in Rapid Response

Revival will contain all information, representations and

warranties upon which there may be any reliance. Any such

contract will also contain an acknowledgment by the Recipient

that it has not relied on any representations or warranties by any

of the Information Providers in applying for Shares in the

Company other than any representations and warranties set out

in such contract.


CONFIDENTIAL

Email: [email protected]

For enquiries

Web: www.rapidresponserevival.com.au

Documents

RRR Pitch Deck